Intraocular pharmacokinetics of anti‐vascular endothelial growth factor agents by intraoperative subretinal versus intravitreal injection in silicone oil‐filled eyes of proliferative diabetic retinopathy: a randomized controlled pilot study

2020 ◽  
Vol 98 (7) ◽  
Author(s):  
Teng‐teng Yao ◽  
Yuan Yang ◽  
Xiao‐liang Jin ◽  
Yi‐xiao Wang ◽  
Ya‐li Zhou ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Diabetic Retinopathy ◽  
Pilot Study ◽  
Growth Factor ◽  
Intravitreal Injection ◽  
Proliferative Diabetic Retinopathy ◽  
Silicone Oil ◽  
Vascular Endothelial ◽  
Randomized Controlled ◽  
Endothelial Growth Factor

scholarly journals Changing of the vascular endothelial growth factor concentration in aqueous humor before and after intravitreal injection of Bevacizumab adjuvant treating complicated proliferative diabetic retinopathy

2021 ◽  
Vol 63 (7) ◽  
pp. 17-21
Author(s):  
Tuan Anh Vu ◽  
◽  
Tuan Thanh Hao Nguyen ◽  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Intravitreal Injection ◽  
Aqueous Humor ◽  
Proliferative Diabetic Retinopathy ◽  
Vascular Endothelial ◽  
Study Results ◽  
Before And After ◽  
Endothelial Growth Factor

This article studies the changing of concentration of vascular endothelial growth factor (VEGF) from the aqueous humor sample, before and after intravitreal injection of Bevacizumab, for treatment of complicated proliferative diabetic retinopathy (PDR) and the correlation with clinical features. This study was implemented with prospective and interventional case series; 1.25 mg of Bevacizumab was injected into the vitreous cavity to treat PDRin 48 eyes of 29 patients. Aqueous humor samples were obtained before intravitreal injection of Bevacizumab and one week after. Study results showed: VEGF concentration decreased from 474.23±361.32 pg/ml to 16.96±18.11 pg/ml (p=0.000) at all eyes after one-week injection. There were no differences in levels of VEGF among groups according to the vitreous haemorrhage, tractional retinal detachment, and retinal fibrosis. Therefore, the study exhibited a better understanding of the role of anti-VEGF in the adjuvant treatment of complicated PDR.

scholarly journals Análise da Revisão Cochrane: Anti-fator de Crescimento Vascular Endotelial na Prevenção da Hemorragia Vítrea Pós-Operatória após Vitrectomia por Retinopatia Diabética Proliferativa. Cochrane Database Syst Rev. 2015;8:CD008214.

2017 ◽  
Vol 30 (7-8) ◽  
pp. 513 ◽  
Author(s):  
David Cordeiro Sousa ◽  
Inês Leal ◽  
João Costa ◽  
António Vaz-Carneiro
Keyword(s):  
Systematic Review ◽  
Vascular Endothelial Growth Factor ◽  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Proliferative Diabetic Retinopathy ◽  
Vitreous Hemorrhage ◽  
Vascular Endothelial ◽  
Cochrane Systematic Review ◽  
Endothelial Growth Factor ◽  
Postoperative Vitreous Hemorrhage

Postoperative vitreous hemorrhage is a complication following vitrectomy for proliferative diabetic retinopathy, delaying visual recovery and making fundus examination and disease follow-up more difficult. Anti-vascular endothelial growth factor drugs such as bevacizumab, when injected in the vitreous cavity, reduce vascular proliferation and their use has been proposed to reduce the incidence of postoperative vitreous hemorrhage. The authors of this Cochrane systematic review evaluated all randomized controlled trials on the pre- or intraoperative use of anti-vascular endothelial growth factor to reduce postoperative vitreous hemorrhage occurrence after vitrectomy in patients with proliferative diabetic retinopathy. The results suggested that the use of intravitreal bevacizumab was effective in reducing early postoperative vitreous hemorrhage (i.e. at four weeks) occurrence, with a good safety profile. This work aims to summarize and discuss the findings and clinical implications of this Cochrane systematic review.

Sign in / Sign up

Export Citation Format

Share Document